Pharmacokinetics, distribution, and metabolism of [ 14C]sunitinib in rats, monkeys, and humans

Drug Metabolism and Disposition

Volumn 40, Issue 3, 2012, Pages 539-555

  Speed, Bill ^a   Bu, Hai Zhi ^b   Pool, William F ^c   Peng, Geoffrey W ^c   Wu, Ellen Y ^c   Patyna, Shem ^c   Bello, Carlo ^d   Kang, Ping ^c  

^a Pharmacokinetics Dynamics and Metabolism   (United Kingdom)

^b 3D BioOptima Co Ltd   (China)

^c PFIZER INC   (United States)

^d Clinical Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; SUNITINIB; SUNITINIB C 14; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEAMINATION; DEFLUORINATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; FECES; FEMALE; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NORMAL HUMAN; OPEN STUDY; OXIDATION; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RADIOACTIVITY; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; URINARY EXCRETION; WHOLE BODY AUTORADIOGRAPHY;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; ANIMALS; BIOLOGICAL AVAILABILITY; CARBON ISOTOPES; CARBON RADIOISOTOPES; FECES; FEMALE; HALF-LIFE; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; MIDDLE AGED; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84857399736     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.042853     Document Type: Article

References (27)

1. Abrams TJ, Lee LB, Murray LJ, Pryer NK, and Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478.
2. Bello C, Bu HZ, Patyna S, Kang P, Peng G, Pool W, Smeraglia J, Sherman L, Garrett M, Klamerus K (2007) A phase I mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib (SU11248) in healthy male subjects (abstract). Proc Am Assoc Cancer Res 48:9072.
3. Brahmer JR, Govindan R, Novello S, Rosell R, Belani CP, Atkins JN, Gillenwater HH, Tye L, Chao R, Socinski MA (2007) Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): results from a phase II study. Proc Am Soc Clin Oncol 25:7542.
4. Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, and Slamon D (2008) A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 61:515-524. (Pubitemid 350275988)
5. Bullock P, Pearce R, Draper A, Podval J, Bracken W, Veltman J, Thomas P, and Parkinson A (1995) Induction of liver microsomal cytochrome P450 in cynomolgus monkeys. Drug Metab Dispos 23:736-748.
6. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, and Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810- 1816.
7. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338. (Pubitemid 44528723)
8. Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, Zhang Q, Sukbuntherng J, Sweeny DJ, Antonian L, and Wu EY (2009) Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol 64:691-706.
9. Hendee WR (1973) Internal Absorbed Dose in Radioactive Isotopes in Biological Research, John Wiley & Sons, Inc., New York.
10. Kulke MH, Lenz H-J, Meropol NJ, Posey J, Picus J, Ryan DP, Bergsland E, Stuart K, Baum CM, and Fuchs CS (2005) Results of a phase II study with sunitinib malate (SU11248) in patients (pts) with advanced neuroendocrine tumors (NETS) (oral presentation). In: The 13th European Cancer Conference (ECCO 13), Paris, 2005 Oct 30-Nov 3, Abstract 718.
11. Loeevinger R and Berman M (1968) A schema for absorbed-dosed calculations for biologically-distributed radionuclides. J Nucl Med (Suppl. 1:9-14.
12. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, and Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 9:327-337. (Pubitemid 36109749)
13. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, and Figlin RA (2007) Sunitinb versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 356:115-124. (Pubitemid 46089672)
14. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, and Pryer NK (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766. (Pubitemid 38019277)
15. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, and Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605. (Pubitemid 36857948)
16. Park BK, Kitteringham NR, and O'Neill PM (2001) Metabolism of fluorine-containing drugs. Annu Rev Pharmacol Toxicol 41:443-470. (Pubitemid 32385895)
17. Patyna S and Peng G (2006) Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys (Abstract 56). Eur J Cancer (Suppl) 4:21.
18. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, and Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513.
19. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, and Lenz HJ (2007) Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25:4793-4799. (Pubitemid 350086483)
20. Scandlyn MJ, Stuart EC, and Rosengren RJ (2008) Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol 4:413-424. (Pubitemid 351728515)
21. Shapiro BH, Agrawal AK, and Pampori NA (1995) Gender differences in drug metabolism regulated by growth hormone. Int J Biochem Cell Biol 27:9-20.
22. Sistla A, Yang WL, and Shenoy N (2006) High-performance liquid chromatographic method for determination of reversible isomers of SU5416. J Chromatogr A 1110:73-806.
23. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, and Scagliotti GV (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650-656. (Pubitemid 351264362)
24. U.S. Food and Drug Administration, Department of Health and Human Services (2011) Part 361-Radioactive drugs for certain research uses. Prescription drugs for human use generally recognized as safe and effective and not misbranded: drugs used in research. Title 21, Code of Federal Regulations, Volume 5. 2011 Apr 1.
25. World Medical Association Declaration of Helsinki (2000) Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000.
26. Zane PA, Brindle SD, Gause DO, O'Buck AJ, Raghavan PR, and Tripp SL (1990) Physicochemical factors associated with binding and retention of compounds in ocular melanin of rats: correlations using data from whole-body autoradiography and molecular modeling for multiple linear regression analyses. Pharm Res 7:935-941. (Pubitemid 20349766)
27. Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Beer TM, Maneval EC, Chen I, Logothetis CJ (2007) Distinct patterns of PSA modulation by single-agent sunitinib before combination with docetaxel and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPCa). Proc Am Soc Clin Oncol 25:5134.